Auscann didn’t just appoint a global big pharma executive as CEO to sell re-branded Canopy products to the Australian market.
...and Canopy didn’t invest a chunk of cash in Auscann to bypass their own supply chain.
The intended path forward seems pretty clear.
-proprietory dose form hard cap aimed at the mainstream global pharmaceutical market, check.
-competent & accredited manufacturer, check.
-reliable & diverse supply of raw materials (resin & buds), check.
-CEO with the skill set, contacts & distribution network to connect the dots, check.
Challenges ahead to be sure, but risk/reward profile suits me.
AC8 Price at posting:
41.5¢ Sentiment: Hold Disclosure: Held
